After successful development of Vaccine Covid-19, the scientific world expects to use MARN technology to erase malaria, other dangerous infectious diseases.

BionTech on July 26 announced that it would invest in a part of the profit from the Covid-19 vaccine according to the technology of Arn information (MRNA) that the company developed with Pfizer partners to serve a fever deal.

We want to help erase the malaria.

If the project is successful, the vaccine will open a new page for the fight against malaria.

Ugur Sahin, CEO of Biontech, affirmed that it will find ways to successfully develop vaccines to prevent malaria, reduce mortality and bring a sustainable solution to Africa with areas that are at risk from this disease.

South African people came to the Multipurpose Test Point of Covid-19, TB and HIV in Johannesburg.

The project received support from the World Health Organization (WHO), the African Disease Control and Prevention Center (ACDC) and the European Union (EU).

We can trust about achieving this goal within a generation, she stressed.

The scientific gender since 2020 shared optimism about Vaccine MARN technology.

BionTech's ambition does not stop at dealing with Covid-19 and malaria.

Another vaccine is developing by Biontech to treat tuberculosis.

The development of vaccines against germs such as bacteria or parasites will be more complicated than the virus.

Encroaching on the new field, Biontech once again competes directly with Oxford University, the unit has successfully developed Astrazeneca vaccine.

This competition in the long term will bring great benefits to Africa, the area is importing nearly 99% of vaccines because there is no self-production capacity.

Free copyright does not create vaccines.

Medical staff in Germinston, South Africa was vaccinated with Covid-19 in May. Photo: AFP.

Instead of copyright transfer, Biontech aims to build a MARN technology manufacturing facility in Africa, thereby helping to solve the problem of Vaccine Covid-19, which is seriously deficient.

The issue of vaccine supply for Africa has been debated for many months but does not achieve progress.

The Covax initiative is still unable to meet the vaccine needs of many low and medium-income countries around the world.

According to the experts on pharmaceutical production, MARN technology can lit up the long-term hope for low-income countries like in Africa.

Some potential partners are considered by biontech cooperation including South Africa, Senegal, Egypt, Morocco and Tunisia.

We believe that the combination of MARN technology and the ability to adjust the immune system correctly will contribute to creating a more effective malaria vaccine, Sahin stressed.